SG Americas Securities LLC Takes Position in uniQure (NASDAQ:QURE)

SG Americas Securities LLC purchased a new stake in shares of uniQure (NASDAQ:QURE) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 17,159 shares of the biotechnology company’s stock, valued at approximately $116,000.

Several other institutional investors and hedge funds have also recently modified their holdings of QURE. Captrust Financial Advisors increased its holdings in uniQure by 1,392.3% in the 2nd quarter. Captrust Financial Advisors now owns 1,940 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,810 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in uniQure by 152.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,231 shares in the last quarter. Covestor Ltd bought a new stake in uniQure in the 1st quarter worth about $50,000. Coppell Advisory Solutions LLC bought a new stake in uniQure in the 2nd quarter worth about $42,000. Finally, BluePath Capital Management LLC bought a new stake in uniQure in the 3rd quarter worth about $27,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Stock Up 0.9 %

QURE stock opened at $4.71 on Friday. uniQure has a twelve month low of $4.61 and a twelve month high of $22.48. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49. The stock has a market cap of $225.33 million, a P/E ratio of -0.73 and a beta of 0.95. The business’s 50-day moving average price is $5.39 and its 200-day moving average price is $6.06.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.01. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. The firm had revenue of $6.69 million for the quarter, compared to analysts’ expectations of $3.20 million. On average, equities research analysts forecast that uniQure will post -4.49 EPS for the current year.

Insider Activity

In other news, COO Pierre Caloz sold 9,455 shares of uniQure stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.47, for a total transaction of $61,173.85. Following the transaction, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Matthew C. Kapusta sold 27,904 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.35, for a total value of $177,190.40. Following the transaction, the chief executive officer now directly owns 440,839 shares of the company’s stock, valued at approximately $2,799,327.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Pierre Caloz sold 9,455 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the transaction, the chief operating officer now directly owns 85,643 shares in the company, valued at $554,110.21. The disclosure for this sale can be found here. Insiders have sold a total of 53,265 shares of company stock valued at $339,845 in the last ninety days. Corporate insiders own 4.05% of the company’s stock.

Wall Street Analyst Weigh In

QURE has been the subject of several research analyst reports. The Goldman Sachs Group downgraded uniQure from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $63.00 to $8.00 in a report on Thursday, February 29th. Mizuho reduced their price objective on uniQure from $10.00 to $7.00 and set a “neutral” rating for the company in a report on Monday, March 4th. StockNews.com raised uniQure to a “sell” rating in a research report on Friday, March 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $28.00 target price on shares of uniQure in a research report on Tuesday, January 16th. Finally, HC Wainwright dropped their target price on uniQure from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, March 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.